norcantharidin has been researched along with Malignant Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bing, Z; Bosenberg, M; Kumar, SM; Liu, S; Martin, JS; Sheng, W; Xu, X; Yu, H | 1 |
| An, WW; Ikejima, T; Onodera, S; Tashiro, S; Wang, MW | 1 |
2 other study(ies) available for norcantharidin and Malignant Melanoma
| Article | Year |
|---|---|
Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Humans; Melanoma; Mice; Mice, Transgenic; Mitochondria; Nuclear Receptor Subfamily 4, Group A, Member 1; Protein Binding; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Mitogen-activated protein kinase-dependent apoptosis in norcan-tharidin-treated A375-S2 cells is proceeded by the activation of protein kinase C.
Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; DNA Fragmentation; Enzyme Activation; Humans; Melanoma; Mitogen-Activated Protein Kinases; Protein Kinase C; Staurosporine | 2005 |